SCHEMBL3207787

SCHEMBL3207787

CCOC(=O)CCNC1CCCCC1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 3/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
THRB P10828 1/20 0.47
ATM Q13315 1/20 0.47
KDM4E B2RXH2 3/20 0.47
POLB P06746 1/20 0.47
CNR2 P34972 1/20 0.44
SMYD3 Q9H7B4 1/20 0.43
CHRM1 P11229 1/20 0.43
ALDH1A1 P00352 5/20 0.42
TSHR P16473 1/20 0.42
MGAM O43451 1/20 0.42
GAA P10253 1/20 0.42
SI P14410 1/20 0.42
MGAM2 Q2M2H8 1/20 0.42
HTT P42858 1/20 0.42
EPHX1 P07099 1/20 0.41
TDP1 Q9NUW8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3532178 0.98 EPHX2 (0.45) EPHX2L3MBTL1THRBATMKDM4E
SCHEMBL3667582 0.95 SMYD3 (0.44) EPHX2L3MBTL1THRBATMKDM4E
SCHEMBL7140606 0.91 SMYD3 (0.50) EPHX2L3MBTL1KDM4EPOLBSMYD3
SCHEMBL2678496 0.90 EPHX2 (0.52) EPHX2L3MBTL1THRBATMKDM4E
SCHEMBL11326316 0.90 EPHX2 (0.52) EPHX2L3MBTL1THRBATMKDM4E
SCHEMBL19188031 0.89 THRB (0.44) EPHX2L3MBTL1THRBATMKDM4E
SCHEMBL6977649 0.88 EPHX2 (0.50) EPHX2L3MBTL1THRBATMKDM4E
SCHEMBL31084448 0.87 EPHX2 (0.52) EPHX2L3MBTL1THRBATMKDM4E
SCHEMBL15858937 0.85 THRB (0.46) L3MBTL1THRBATMKDM4EPOLB
SCHEMBL20389672 0.85 EPHX2 (0.48) EPHX2L3MBTL1THRBATMKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113089373-B Medical high-strength dialysis paper and preparation method thereof 华邦古楼新材料有限公司 2022-06-17 CN claimed
CN-113089373-A Medical high-strength dialysis paper and preparation method thereof 华邦古楼新材料有限公司 2021-07-09 CN claimed
EP-0449989-A1 6,7 DIHYDROPYRROLO 3,4-c] PYRIDO 2,3-d] PYRIMIDINE DERIVATIVES Sloan-Kettering Institute For Cancer Research (US) 1991-10-09 EP claimed
WO-1990007496-A1 6,7 DIHYDROPYRROLO[3,4-c] PYRIDO[2,3-d] PYRIMIDINE DERIVATIVES SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 1990-07-12 WO claimed
CN-113089373-B Medical high-strength dialysis paper and preparation method thereof 华邦古楼新材料有限公司 2022-06-17 CN disclosed
CN-113089373-B Medical high-strength dialysis paper and preparation method thereof 华邦古楼新材料有限公司 2022-06-17 CN disclosed
CN-113089373-A Medical high-strength dialysis paper and preparation method thereof 华邦古楼新材料有限公司 2021-07-09 CN disclosed
CN-113089373-A Medical high-strength dialysis paper and preparation method thereof 华邦古楼新材料有限公司 2021-07-09 CN disclosed
EP-2881384-B1 PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND TAISHO PHARMACEUTICAL CO LTD (JP) 2018-05-30 EP disclosed
US-9422240-B2 Partially saturated nitrogen-containing heterocyclic compound TAISHO PHARMACEUTICAL CO., LTD (JP) 2016-08-23 US disclosed
EP-1890703-B1 PYRIMIDINE COMPOUNDS AS CHEMOKINE RECEPTORS INHIBITORS TAIGEN BIOTECHNOLOGY CO LTD (TW) 2016-05-11 EP disclosed
US-20150175541-A1 PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND TAISHO PHARMACEUTICAL CO., LTD (JP) 2015-06-25 US disclosed
WO-2007033137-A1 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2007-03-22 WO disclosed
US-20070060578-A1 5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2007-03-15 US disclosed
US-20070060577-A1 5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA N.V. (BE) 2007-03-15 US disclosed
EP-0449989-A1 6,7 DIHYDROPYRROLO 3,4-c] PYRIDO 2,3-d] PYRIMIDINE DERIVATIVES Sloan-Kettering Institute For Cancer Research (US) 1991-10-09 EP disclosed
WO-1990007496-A1 6,7 DIHYDROPYRROLO[3,4-c] PYRIDO[2,3-d] PYRIMIDINE DERIVATIVES SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 1990-07-12 WO disclosed
US-4925939-A 6,7-dihydropyrrol[3,4-c]pyrido[2,3-d]pyrimidine derivatives SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 1990-05-15 US disclosed
US-4421693-A INSECTICIDES, MITICIDES OR NEMATOCIDES OTSUKA CHEMICAL CO., LTD. (JP) 1983-12-20 US disclosed
US-4413005-A 2,3-DIHYDRO-2,2-DIMETHYLBENZOFURAN-7-YL DERIVATIVES OTSUKA KAGAKU YAKUHIN KABUSHIKI KAISHA (JP) 1983-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150175541-A1 PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND EGLN2, EGLN3, EGLN1 EPHX2 1144/4885L3MBTL1 3915/4885THRB 3015/4885
US-20070060578-A1 5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase FLT3, FES, FGR EPHX2 1919/4885L3MBTL1 3067/4885THRB 1322/4885
US-20070060577-A1 5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase FLT3, FES, FGR EPHX2 2161/4885L3MBTL1 2111/4885THRB 968/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.